Numedicus
Private Company
Funding information not available
Overview
Numedicus is a private, UK-based biotech firm specializing in the systematic identification of new uses for existing drugs through its extensive, experimentally validated database. Founded in 2015, the company employs a virtual model, collaborating with partners to advance repurposed candidates through clinical development, as evidenced by its portfolio of licensed programs. Led by industry veteran David Cavalla, Numedicus targets significant unmet medical needs across diverse therapeutic areas, offering a de-risked and capital-efficient approach to drug development.
Technology Platform
DrugRepurposing Online database containing over 4,000 potential new uses for existing compounds, with a focus on functional, experimentally validated content to identify drug repurposing opportunities and support method-of-use patent generation.
Opportunities
Risk Factors
Competitive Landscape
Numedicus competes with other drug repurposing firms, both data-centric (e.g., Biovista, Recursion) and clinically focused, as well as internal efforts at large pharma. Its competitive edge lies in its curated, experimentally validated database and the deep domain expertise of its leadership in securing IP and advancing projects clinically.